icon-    folder.gif   Conference Reports for NATAP  
  IAS 2017: Conference on HIV Pathogenesis
Treatment and Prevention
Paris, France
July 23-26 2017
Back grey_arrow_rt.gif
Adherence intentions, long-term adherence and HIV acquisition among PrEP users in the PROUD open-label randomised control trial of PrEP in England
  Reported by Jules Levin
9th IAS Conference on HIV Science (IAS 2017), July 23-26, 2017, Paris
M. Gafos1, E. White1, D. White2, A. Clarke3, V. Apea4, E. Brodnicki1, N. Mackie5, A. Sullivan6, G. Schembri7,
C. Lacey8, R.Horne9, D. Dunn1, S. McCormack1, M. Desai10; 1MRC Clinical Trials Unit at UCL,, London, 2Heart of England NHS Foundation Trust,, Birmingham,,
3Royal Surrey Sussex County Hospital, Brighton, 4Barts Health NHS Trust, London, 5Imperial College NHS Foundation Trust, London, 6Chelsea and Westminster Hospital NHS Foundation Trust, London, 7Central
Manchester University Hospitals NHS Foundation Trust,, Manchester, 8York Hospitals NHS Foundation Trust, York, 9UCL, School of Pharmacy, London, 10Public Health England, London.





1McCormack, S, et al. "Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial." The Lancet 387.10013 (2016): 53-60.
2Dolling, D, et al. "An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxis." Trials 17.1 (2016): 163